A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms HORIZON
- Sponsors Oncopeptides
- 16 Nov 2016 Status changed from not yet recruiting to recruiting.
- 09 Nov 2016 New trial record